Endometrial Dedifferentiated Carcinoma
Associated Genetic Biomarkers
NCI Definition: A carcinoma that arises from the endometrium and is characterized by the presence of an undifferentiated carcinomatous component and a second component of either FIGO grade 1 or 2 endometrioid carcinoma. 
Endometrial dedifferentiated carcinomas most frequently harbor alterations in PTEN, ARID1A, ARID1B, and PIK3CA .
PTEN Mutation, ARID1A Mutation, ARID1A Frameshift, ARID1B Mutation, and PIK3CA Mutation are the most common alterations in endometrial dedifferentiated carcinoma .
There is 1 clinical trial for endometrial dedifferentiated carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains endometrial dedifferentiated carcinoma as an inclusion criterion, 1 is phase 2 (1 open).
ER and PR are the most frequent gene inclusion criteria for endometrial dedifferentiated carcinoma clinical trials .
Abemaciclib and fulvestrant are the most common interventions in endometrial dedifferentiated carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.